Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by <i>BRCA</i> status: a retrospective cohort study.

Overall survival (OS) did not reach statistical significance, though it was clinically meaningful ( Table 1 ). 10 , 11 Conversely, the PRIMA trial evaluated the impact of niraparib as maintenance in patients with stage III and IV ovarian cancer after first-line platinum-based chemotherapy without restriction based on HRD status.

also in 111,027 other papers